Genomics & Precision Medicine

ACM Global Laboratories operates across four continents, delivering central laboratory services, bioanalysis, and toxicology to sponsors running clinical trials at every stage of development. With facilities in Rochester (NY), York (UK), Singapore, and Mumbai, the organisation functions as a single integrated laboratory network rather than a collection of regional outposts, giving study teams a consistent standard of science regardless of trial geography. Central Lab and Bioanalytical Capabilities The central lab division handles routine safety testing, biomarker testing, flow cytometry, radiopharmaceutical services, and pathology, alongside the full spectrum of clinical trial testing. Sponsors with urgent timelines can access dedicated rescue and expedite study pathways, reducing the risk that slow laboratory turnaround becomes the critical path on a programme. Sample logistics are supported by customised collection kits and advanced sample tracking, which simplifies the co-ordination burden for site staff and CRO project managers alike. The bioanalytical services portfolio covers large molecule bioanalysis, advanced pharmacokinetic bioanalysis, pharmacodynamic biomarker analysis, controlled substance analysis, and work on novel drug delivery systems. Specialist capability extends to nicotine research and cannabinoid testing, areas that require particular regulatory sensitivity. COVID-19 research studies are also accommodated within the central lab offering. Toxicology and Workplace Testing The toxicology division provides drug monitoring, workplace testing, and reference laboratory testing, serving both clinical development programmes and occupational health requirements. This breadth makes ACM Global Laboratories relevant to pharmaceutical, biotech and corporate clients whose needs span the regulated and non-regulated sectors. Client-facing resources include a self-service portal, the ACM QuikReport tool, and LabStar, a platform that supports site training and sample management. The combination of these digital tools with a global physical footprint positions the organisation well for decentralised and hybrid trial designs that are now common across the industry. ACM marks fifty years of operation, a milestone that underscores the depth of institutional experience behind its service model. Further information is available at acmgloballab.com.

As the only FDA-inspected bioanalytical laboratory of its type in Australia, Agilex Biolabs occupies a distinctive position in the Asia-Pacific clinical trial services market. Based in Australia, the company serves contract research organisations and sponsors requiring rigorous bioanalytical and toxicology support throughout drug development. The laboratory's core capability is pharmacokinetics (PK) analysis , covering the full time course of drug absorption, bioavailability, distribution, metabolism, and excretion. Complementing this is pharmacodynamics (PD) work, which addresses the biochemical, physiological, and molecular effects of a therapeutic on the body. Together, these services provide sponsors with an integrated view of drug behaviour in clinical studies. Agilex Biolabs operates across several analytical disciplines. LC-MS/MS bioanalysis and immunoassays (ligand binding assays) underpin small and large molecule quantification. The team also conducts immunogenicity testing, including anti-drug antibody and neutralising antibody assays, alongside vaccine and cell-based immunology assays and flow cytometry. Biomarker services are an active component of the offering, providing efficacy, safety, and pathology data relevant to the indication under investigation. For multi-site programmes, the laboratory provides end-to-end central lab services, managing the entire sample lifecycle including kit production and distribution to clinical sites. Off-the-shelf assays are available to reduce time and cost for sponsors with more standard bioanalytical requirements. The company's FDA-inspected status makes it a credible option for global programmes requiring a compliant Southern Hemisphere facility, particularly where an Australian clinical footprint or regulatory alignment is relevant to the development strategy. Further information is available at agilexbiolabs.com.

At the forefront of a differentiated approach to cancer treatment, Akari Therapeutics is a Nasdaq-listed oncology biotechnology company (ticker: AKTX) developing a new class of antibody-drug conjugates (ADCs) built around a novel payload, PH1, that targets RNA splicing rather than the tubulin inhibitors or DNA-damaging agents used by existing ADC programmes. Headquartered in New York, the company operates a proprietary ADC discovery platform designed to generate and optimise candidates against any antigen target of interest. The lead programme, AKTX-101, is directed at the Trop2 receptor expressed on cancer cells. A proprietary linker enables AKTX-101 to deliver the PH1 payload directly into tumours with the aim of minimising off-target effects, differentiating it from first-generation ADC approaches that rely on tubulin or DNA-damaging payloads. Trop2 is a clinically validated target in multiple solid tumour indications, and Akari's RNA-splicing mechanism of action represents biology not yet exploited by currently approved ADC therapies. The next-generation ADC discovery platform is engineered to accelerate candidate generation and to tailor individual ADCs to specific oncology applications across multiple antigen targets. By combining a distinctive payload class with a flexible discovery engine, Akari positions itself within the broader precision oncology space as a company pursuing mechanistic differentiation from first-wave ADC programmes as its pipeline advances. Further information is available at akaritx.com.

Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals. Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio. A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept , a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making. The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance. Further information is available at alacris.de.

A proprietary platform for mining human antibody repertoires sits at the core of Alchemab Therapeutics , a clinical-stage biotechnology company working to identify novel drug targets and therapeutics by reverse engineering the biology of resilient patients. Rather than starting from disease biology alone, the approach begins with well-defined patient samples drawn from individuals who are susceptible to a condition yet remain protected from it, using deep B cell sequencing and computational analysis to identify convergent protective antibody responses across that population. The platform is designed to surface drug candidates that conventional discovery programmes are unlikely to find, making it particularly well suited to hard-to-treat diseases where existing therapeutic options remain limited. Alchemab has built its initial pipeline around neurodegenerative conditions and oncology, two areas where unmet medical need remains high and mechanistic understanding of protective immunity is still emerging. Access to the highly specialised patient samples that power the platform depends on a network of partnerships with patient representative groups, biobanks, industry partners, and academic institutions. These collaborations are central to the company's discovery model, ensuring that the antibody repertoire data feeding the computational analysis pipeline reflects genuine protective biological signals rather than population averages. Alchemab is led by Chief Executive Officer Jane Osbourn, OBE, FMedSci, PhD, who brings substantial scientific and commercial experience from the biotech and pharmaceutical sector. The broader executive and scientific leadership team is described as combining deep domain expertise with an ambitious development agenda across the company's growing pipeline. Further information is available at alchemab.com.

Mining what it describes as the deepest layers of plasma knowledge, Alkahest combines artificial intelligence, multiomics analysis and real-world data with deep plasma protein expertise to drive drug discovery. A subsidiary of Grifols, the California-based research company focuses on identifying and developing transformative therapies derived from the science of plasma. The scientific foundation underlying Alkahest's pipeline rests on the premise that the plasma proteome is in constant flux, influencing human biology in ways that can both sustain and undermine health. According to the company, alterations in plasma protein concentration and conformation are linked to multiple drivers of disease, with changes appearing years before clinical diagnosis. This positions plasma proteins as potential early biomarkers capable of informing prediction, diagnosis and treatment. A significant competitive asset is access to Grifols' plasma repository, which the company describes as one of the world's largest collections, comprising more than 100 million plasma samples gathered over nearly 15 years. The dataset spans thousands of disease states and is linked to real-world health records. Alkahest applies advanced analytical and integrative multiomics capabilities to this resource to build an evolving picture of the protein network and its relationship to human ageing and disease. The company's work sits at the intersection of plasma biology, data science and therapeutic development, representing a scientifically grounded approach to conditions where conventional small-molecule or antibody strategies have faced limitations. Further information is available at alkahest.com.

Regulatory navigation for IVD and companion diagnostics sits at the core of what ARC Regulatory does. The firm operates as a specialist contract research organisation serving pharmaceutical, diagnostics and laboratory clients that require expert guidance through the clinical and compliance demands of in vitro diagnostic and CDx development. The service portfolio spans four principal disciplines. On the regulatory side, the team supports clients in navigating global frameworks applicable to IVD and CDx programmes. Clinical monitoring is delivered with a global presence, with a particular focus on IVD and CDx study designs. Quality services cover QMS auditing, risk management and QMS implementation, while ARC Research Laboratories provides IVD development and validation using advanced technologies. The CRO offering guides sponsors from strategy through to study close-out across every phase of IVD and CDx clinical development. A dedicated IVD Clinical Study Sponsor Delegation service allows clients to initiate and manage IVD studies through a single trusted partner. The firm's proprietary ARC360 platform is positioned to accelerate clinical performance studies, supporting monitoring of central testing laboratories across the full clinical development life-cycle. Sector coverage reflects the firm's cross-disciplinary positioning. Pharmaceutical clients benefit from support in translational biomarker programmes and early clinical trial authorisations, including risk-based monitoring of central testing laboratories. Diagnostics companies receive R&D compliance support and full-service CRO capability for clinical performance studies. Laboratory clients access analytical testing capabilities aligned to their regulatory obligations. Further information is available at arc-regulatory.co.uk.